Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Results from CheckMate-227 : Immune combination reaches PFS endpoint

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.04.18
Views: 4850

Dr Matthew Hellmann - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Hellmann presents results at AACR 2018 from CheckMate-227, assessing a combination of nivolumab and ipilimumab in cases of newly diagnosed non-small cell lung cancer with high mutational burden.

The 139 patients treated with the combination were 42% less likely to have their disease to progress compared to those treated with chemotherapy.

Overall survival data are still maturing.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation